[A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment].

Abstract

Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is the template for HBV replication. Currently, there is a lack of therapeutic drugs that directly target cccDNA. Therefore, blocking cccDNA supplements as fast as possible and reducing the existing cccDNA is the key to achieving a complete cure of chronic hepatitis B. Previous studies have suggested that cccDNA had a long half-life, but a recent study showed that it only took a few months to update cycle of cccDNA pool, and its number was much less than previously predicted. In the future, with the advent of new antiviral drugs that can completely inhibit HBV replication, it is expected that the cccDNA pool will be completely cleared due to its supplement complete blockade, so as to achieve virological cure of chronic hepatitis B.

• Authors: L Gao, T H Mao, S W Peng, J Wang, X M Chen, F M Lu
• Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (Zhonghua Gan Zang Bing Za Zhi) Vol. 30 Issue 1 Pg. 99-102 (Jan 20 2022) ISSN: 1007-3418 [Print] China
• PMID: 35152678 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• DNA, Circular
• DNA, Viral

Topics

• Antiviral Agents (pharmacology, therapeutic use)
• DNA, Circular (genetics)
• DNA, Viral
• Half-Life
• Hepatitis B (drug therapy)
• Hepatitis B virus (genetics)
• Hepatitis B, Chronic (drug therapy)
• Humans
• Virus Replication